1AlocadoTMEffect of AlocadoTMcomplex treatment on PASI scoreson psoriasis patientsProspective Clinical StudyFinal report20...
2CONTENTS1. Introduction……………………..3-52. Study design…………………….5-63. Results……………………………7-134. Discussion……………………….145. Concl...
3IntroductionKedo Eurocosmetics Ltd. and Spider Pharm Industries Ltd. entered an agreement in September2006, to test the A...
4maintenance therapy it is of utmost importance that they be well tolerated by the patient, withoutany side effects.There ...
56. A unique composition of natural oils (mainly Avocado), Aloe Vera extract and salt fromthe Dead Sea (not reaching salt ...
6We began testing Alocado™products in September 2006. It was an open clinical prospectivestudy over a period of one year. ...
7ResultsWhen starting the Alocado™treatment, we tried to choose patients who had not been treated withany steroids or othe...
82122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970711272.2483.113.78.61...
97273747576777879808182838485868788899091929394959697989910010110210310410510610710810911011111211311411511611711811912012...
10123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162...
11173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212...
12index before the treatment) and by 65% in the end of the 3 weeks of the treatment (35%compare to the PASI index before t...
13Figure 2.Figure 3.
14DiscussionPsoriasis is a chronic inflammatory skin disease with a high social and psychological impact onthe quality of ...
15References:1. O. Braun - Falco. G. Plewig, H.H .Wolff, W.H.C Burgdorf: Dermatology Second,Completely Revised Edition, Sp...
16Appendix 1I. ATOPIC DERMATITISClinical test for ALOCADO™• A woman of 29 years of age• Suffering from Atopic Dermatitis f...
17II. PSORIASISClinical test for ALOCADO™• 75 years old• PASI index at start 39.2 for the past 15 years no improvement wha...
18III. PSORIASISClinical test for ALOCADO™• 68 years old lady• PASI index at start 26, for the past 10 years no improvemen...
Upcoming SlideShare
Loading in...5
×

Alocado™ clinical study report dr angela ruban

210

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
210
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
8
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Alocado™ clinical study report dr angela ruban

  1. 1. 1AlocadoTMEffect of AlocadoTMcomplex treatment on PASI scoreson psoriasis patientsProspective Clinical StudyFinal report2008Prepared for:Spider pharm Industry Ltd.Arad IsraelPrepared by:Teva Pharmaceuticals Ltd.HungaryAnalyzed, Summarized and Written by:Dr. Angela Ruben, PhD in Clinical Pharmacology
  2. 2. 2CONTENTS1. Introduction……………………..3-52. Study design…………………….5-63. Results……………………………7-134. Discussion……………………….145. Conclusion……………………….146. References………………………..157. Appendix 1: case reports………16-18
  3. 3. 3IntroductionKedo Eurocosmetics Ltd. and Spider Pharm Industries Ltd. entered an agreement in September2006, to test the Alocado™ product line on volunteers suffering from psoriasis as requested byTeva Pharmaceuticals Ltd. Hungary. This document contains the test results, which are availablefor anyone wishing to be informed about the products. Our aim is to address physicians,specialists (dermatologists), pharmacists and patients all at the same time.1. About Psoriasis:Psoriasis is a classic and common dermatological condition. It is defined as follows: an“inflammatory skin condition with increased epithelial proliferation, characterized by infiltratedplaques and silvery scaling”. According to international statistics 2-3% of the overall populationsare affected by this condition in varying degrees.In Hungary, the estimated number of patients lies between 200,000 and 300,000, although muchfewer visit their physicians, because part of them has already lost faith in receiving effectivetreatment; the other reason for not seeing a physician is that they are in remission and do not seeits importance. The causes of psoriasis are still unclear, but research has significantly advancedour understanding concerning the inflammatory process and the immunological background ofthe illness.The cause of this condition is believed to be genetic in nature. The condition is characterized byan increased sensitivity of the skin, reacting to external and internal stimuli. These stimuli are theso-called “provoking factors." The most important provoking factors are mechanical (injury orirritation of the skin), immunological, metabolic stimuli, and provocation by medicine and stress.A characteristic feature of the illness is the deterioration of quality of life. This is not a life-threatening illness, and its gravity is determined not by the physician, but the patient. Thiscondition influences the patient’s everyday life as well as their social and working activities.Deterioration of the quality of life due to psoriasis can be as serious as that caused by heartdisease or depression.Clinically speaking, it is the most versatile skin disease. The most often affected parts of thebody are: the scalp, the knees, the elbow, the buttocks, the genitalia, the navel, the flexures andthe nails. Its most frequent forms: thick, silvery plaque, extensive, inflammatory plaque, tiny,punctiform lesions and incidental small blisters. From a medical point of view, the degrees ofillness can range from an asymptomatic state through mild symptoms, with isolated plaques topersistent, thick plaques; from a gradual spread, to a degree, when joints are also affected and thecomplete surface of the skin is covered by erythroderma.According to Prof. Christopher Griffith, the gravity of the illness depends on the degree ofdeterioration of quality of life, the resistance to therapy and the degree lesion spreading.Seeing as psoriasis is an illness that influences the quality of life and its gravity is determined bythe patient, the physician compares his or her own findings with the evaluation of the patient andoffers the patient all available therapeutic alternatives. Finally, they will be able to mutuallychoose the best one. The therapy can be either local or system ic.Local treatment consists of two phases: the first is stopping acute symptoms, and the second ismaintaining therapy with the aim of avoiding a relapse. As for the medication used in
  4. 4. 4maintenance therapy it is of utmost importance that they be well tolerated by the patient, withoutany side effects.There are very few preparations used so far, that comply with the above requirements.Traditional treatment possibilities for the acute phase are: coal tar, local corticosteroids, vitaminD analogues, local retinoids, and keratolytic agents (compounds containing salicylic acid, forexternal application). Besides these, Photo-therapy (PUVA, UVB) and bath therapy may also beapplied.1.The above therapies are effective, but they have several side effects:2.Corticosteroids can cause atrophy of the skin; vasodilation may occur fungal or bacterialinfections may emerge.3. Vitamin D may be irritating and expensive.4.The application of coal tar and some of the photo-therapies in large doses are carcinogenic.5.Salicylic acid in high concentrations is irritating.From the list of above-mentioned therapies only vitamin D is suitable for maintenance therapy.So the need for a phase-specific, non-aggressive (non-irritating) maintenance therapy is justified.2. About Alocado™treatmentThe Alocado™product line was developed in 1988 based on formulas developed by physiciansand pharmacists working in clinics near the Dead Sea. At that time, it was recognized that thesurroundings, the water and the mud of the Dead Sea had a healing effect on the patientssuffering from skin diseases. This was also the time when some publications on side effects anddisadvantageous features of steroids appeared. Sea minerals are Nature’s ultimate supplement formaintaining healthy skin. The minerals essential to well-functioning skin – magnesium, calcium,potassium and sodium – naturally attract and retain water and are known as Natural MoisturizingFactors (NMF). As a person matures, the NMF levels of the body gradually become depleted,lessening the body’s ability to retain the proper moisture levels needed to prevent skin aging.Urban pollution, the ongoing exposure to the elements and the fast-paced lifestyles we live, alltake their toll. Dead Sea mineral formulae help to reactivate the skin’s natural ability to hydrateand replenish itself and restore its natural suppleness. Realizing these facts, the inventors wereinspired to develop a range of products solving all varying problems using a phase specific rangeof products that was a revolutionary departure from the “all in one” existing medicines. Duringtheir work, they could make use of some publications analyzing therapeutic effects of somevegetable oils like Avocado oil, and the Aloe Vera extract. Besides this, patients wished to enjoyremission not only for a week for as long as their treatment at the Dead Sea lasted, but for alonger period of time. This was made possible by being able to take these natural remedies backhome.Advantages of the Alocado™product line are as follows:1.It does not contain steroids.2.It does not contain tar.3.It does not contain synthetic vitamin D.4.The acid content never exceeds 2%.5.The active ingredients are combined with very strong emollients.
  5. 5. 56. A unique composition of natural oils (mainly Avocado), Aloe Vera extract and salt fromthe Dead Sea (not reaching salt concentration levels that could irritate skin).7.There are special products to treat different symptoms, including open wounds.8.We offer products for maintenance therapy to be used in state of remission to contribute topalliate symptoms of the next relapse.9.These products don’t have side effects neither after short- nor after long-term treatment..Study design:1. Psoriasis study group:1.Gender: 209 volunteers’ women and men as equal.2.Age: 18-75 years old3.Health conditions: stable psoriasis at least last 12 months, PASI >2, body or/and head areaffected.4.Background: varied5.Duration:September 2006-September 20076.Termination:After 3 weeks of the treatment.7.Report:Each doctor was follow-up his patient weekly and giving the PASI score that wasdocumented in personal file of each patient. The mean PASI score was calculated for eachpatient and presented in the final report.8.Treatment:The follow Alocado™products were used in the current clinical study:Product nameAlocado ™CreamAlocado ™OintmentAlocado ™PastaAlocado ™GoldAlocado ™Skin SoftenerAlocado ™SilverAlocado ™Bath OilAlocado ™Body OilAlocado ™LotionAlocado ™Scalp OilAlocado ™Zi-ConAlocado ™Zal-ConAlocado ™ShampooAlocado ™Hair Conditioner
  6. 6. 6We began testing Alocado™products in September 2006. It was an open clinical prospectivestudy over a period of one year. 208 volunteers were recruited to take part in the test, which wasnot launched at the most favorable period, because psoriasis generally relapses when coldweather is to be expected. Baseline data were collected along with the dermatologicalexamination, i.e. personal data, medical history, and all medications taken before and at the timeof this examination were recorded. The state of the skin was photographed. The exclusioncriteria were unstable psoriasis, children, pregnancy, lactation, history of any thyroid disorderand severe systemic illnesses. The patients were assessed at the end of 2 and 3 weeks by 55Dermatologists; each doctor treated and follow-up five volunteers. The volunteers were self-treated by different combination of the Alocado™products daily and according to the instructionof the Dermatologist. Once a week, the volunteers were checked by the same doctor and theeffect of the treatment was evaluated using PASI index. The PASI index widely accepted inspecialist literature to establish condition changes.We established values on the basis of PASI index from the starting state of illness, and during therepeated follow-ups.A short summary on PASI:The objective skin condition of the patient is expressed by the so called PASI index. This is aninternationally accepted index to demonstrate the state of the skin and to establish efficacy of thetherapy. The index evaluates the main symptoms of psoriasis: erythema, induration, and scaling,and the size of the affected area are taken into consideration as well. All these factors are takeninto account in the regions of the head, the upper limbs, the torso and the lower limbs. Usingdifferent multipliers a relative number is achieved from the sum of these values. This relativenumber is not quite perfect; e.g. changing from PASI 20 to PASI 10 is much easier than tochange from 10 to 5. There is a version of this index where the patients analyze the valuesthemselves. (This happened in our case, when we had weekly or bi-weekly phone consultationswith the patients.)Since psoriasis is an illness influencing the quality of life, it is the patient who evaluates theillness most precisely; his or her opinion is crucial. The results are expressed as mean ± SD.Students unpaired t-test was used for statistical analysis of the data. Level of significance wasP<0.005.The objectiveThe objective of our study was to assess the clinical efficacy of Alocado™complex treatment inpsoriasis.Administering Alocado™products, our aim was to give emollient, nourishing and calmingpreparations to the patient. These products are phase-specific, meaning that they always exerttheir effect against the most irritating symptom, and they support maintenance therapy inconjunction with drug therapy or without. The products prolong the period between relapses andmake the patients feel more comfortable with their skin.
  7. 7. 7ResultsWhen starting the Alocado™treatment, we tried to choose patients who had not been treated withany steroids or other medicines within a given period before the test. However, taking thesepreparations was not a criterion for exclusion, since it is necessary to have some emollienttreatment for those who took the aforementioned medication.In any cases, improvement could be observed based on the regular application of the Alocado™products. When stopping it, the skin’s condition could deteriorate in some cases the conditions asit was before the treatment. We observed that the efficacy of the products, and the response tothem could be increased by applying the appropriate Alocado™product several times a day. Ithas been observed that application 4 times daily (this dosage proved to be necessary to achievemaximum efficacy) resulted in the fastest improvement.Throughout the treatment, we had to change products with many patients, because Alocado™products are phase-specific, and a different product is recommended depending on thepredominant symptom (scaling, inflammation, infiltration). In patients showing improvement,the use of the compound called Gold should be emphasized, having a soothing effect on theitching, excoriated parts of the skin, which quickly epithelized and the patient soon becameasymptomatic.1. Three weeks after the treatment with Alocado™complex all 208 patients showedsignificant improvement in their symptoms. The positive effect of the treatment wasobserved already after the first week of the treatment. The Table 1 summarized PASIindex scores as per follow-up. As it can be seen in the table the positive effect of thetreatment was achieved independently on the severity of the disease or on the affectedarea percent.Patients PASINumber 1stweek 2ndweek 3nd week1234567891011121314151617181920434.67.46.811.37.12.719.18.75.41.82.62.27.22.84.14.44.912.63.22.43.64.269.84.81.213.85.84.41.411.85.62.33.10.9311.92.81.52.12.93.27.64.719.22.6310.71.231.61.30.92.56.6
  8. 8. 82122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970711272.2483.113.78.612.49.122.61.33.135.6122.47.42.410.93.725.23.65.245.23.65.20.89.923.57.23.621.67.24.81.611.23.14.49.98.47.248.426.445.20.7211.6241.87.47.90.90.86.11.22.212.11.34.871.84.21.86.63.1241.442.841.440.8923.363185.441.48.82.13.788.26.63.26.614.71.640.4151.4201.45.25.70.50.45.210.50.60.60.81.671.22.91.23.331.61.211.411.411.20.75.419.93.21.65.11.81.412.81.32.54.57.543.22.48.71.21
  9. 9. 9727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211228.85.443.65.62.62.92.25.43.34.41.842.5420.77.8213.2421.81.81.84.73.59.95.212.74.45.62.25.42.44.84.82.95.12.29.6411.92.29.77.89.411.215.57.24.63.61.43.322.51.84.833.61.63.22.23.620.761.65.62.81.81.61.41.64.12.8820.82.23.64.51.84.523.63.62.141.67.61.57.81.68.165.74.78.93.43.41.212.50.71.71.23.62.11.41.221.53.21.60.52.41.421.21.41.20.81.42.52.45.51.40.71.91.23.11.21.81.41.42.81.53.41.23.612.50.54.31.52.83.56.2
  10. 10. 1012312412512612712812913013113213313413513613713813914014114214314414514614714814915015115215315415515615715815916016116216316416516616716816917017117217.320.622.410.69.815.826.446.81315.413.526.117.917.663.36.45.62.2413.24.46.62.831.22.225.226.524.42.28.43.641174525.619.218.64.4220.420.5184141.841.4332647.81313.514.75.17.79.620.438.212.8910.517.115.912.83.62.75.241.82.89.63.54.81.824.67.81.822.622.21.87.82.835.211.436.822.713.2153.51.610.212.213.229.819.430.8249.538.14.37.25.82.43.37.27.218.95.80.6612.18.56.21.211.820.61.65.62.91.61.617.86.61.620201.66.6117.43.421.59.46.88.72.90.710.211.56.416.515.616.514.72.435.9
  11. 11. 1117317417517617717817918018118218318418518618718818919019119219319419519619719819920020120220320420520620720820921021121221341.535.343.8892442249.37.67.820.17.511.47.812.423.241.126.119.444.249.523.628.347.3253324.327.418141618.222.238.87.23.9182.533.721.926.26671686.54.47.29.53.65.94.20.51.812.927.911.35262819.525.138.419.615.810.79.41813.21617.516.536.67.20.615.61.633.424.827.1333563.13.13.94.73.62.92.60.50.44.816.92.84.514.817.813.618.628.910.811.84.63.685.31213.91426.85.60.6121.6As it can be seen in Figure 1 the PASI was decreased by 28% after 2ndweek of the treatment(72% compare to the PASI index before the treatment) and by 55% in the end of the 3 weeksof the treatment (45% compare to the PASI index before the treatment). These resultsdemonstrating a high and very fast significant positive effect of the Alocado™complextreatment (unpaired t- test p<0.001). Furthermore, this effect was more remarkable in thepatients with moderate – severe psoriasis (PASI above 7). As it can be seen in the Figure 2the PASI was decreased by 34% after 2nd week of the treatment (66% compare to the PASI
  12. 12. 12index before the treatment) and by 65% in the end of the 3 weeks of the treatment (35%compare to the PASI index before the treatment) (unpaired t- test p<0.001).The most important was the fact that no side effects were reported during the period of thetreatment and within half year later as well.2. Besides the significant improving in the symptoms, in 107 patients was observedsignificant reducing in the percent of the affected area of the body, as can be seen in theFigure 3. After 1stweek of the treatment with Alocado™complex the percent of theaffected area of the body was reduced by 8% as compare to the beginning of thetreatment (32% versus 40%) and by 23% in the end of the 3 weeks of the treatment (17%versus 40%) (unpaired t- test p<0.001).Figure 1.
  13. 13. 13Figure 2.Figure 3.
  14. 14. 14DiscussionPsoriasis is a chronic inflammatory skin disease with a high social and psychological impact onthe quality of life of patients. Literature reports that psoriasis can cause a physical and mentaldisability similar to other medical diseases, like hypertension and diabetes, and psychologicaldistress can influence the rate of withdrawal during standard therapy, because patients who feelworse spend less time caring for their psoriasis.The Dead Sea region is recognized worldwide for its efficacy in the treatment of dermatologicaldiseases, particularly Psoriasis, Atopic Dermatitis, Vitiligo, and Mycosis Fungoides. Seaminerals are Nature’s ultimate supplement for maintaining healthy skin. The minerals essentialto well-functioning skin – magnesium, calcium, potassium and sodium – naturally attract andretain water and are known as Natural Moisturizing Factors (NMF). As a person matures, theNMF levels of the body gradually become depleted, lessening the body’s ability to retain theproper moisture levels needed to prevent skin aging.We conducted a prospective clinical trial on 208 patients affected by mild to severe psoriasisundergoing Alocado™complex therapy. We recorded a significant reduction of the meanPsoriasis Area and Severity Index (PASI) index in all 208 patients who completed the three-week course and an improvement of the ‘quality of life’ of patients. In addition, the recurrence ofthe symptoms 6 months later without treatment that was observed in few cases was usually lesssevere than the previous attack. It should be mentioned that no side effects were observed. Thegood efficacy obtained by this treatment, and the psychological impact on the quality of life ofpatients, demonstrated that Alocado™complex therapy could be a very good option for thetreatment of a chronic disease associated with psychological distress, like psoriasis, particularlywhen the patient is affected by other diseases, and we cannot use any systemic psoriasis drug.What is not less important that this treatment is more cost-effective than many other treatments.ConclusionBased on these results, it may be concluded that the phase-specific, emollient, palliative naturalcompounds of the ALOCADO™product line offer a highly effective, very fast and safealternative for the treatment of psoriasis.
  15. 15. 15References:1. O. Braun - Falco. G. Plewig, H.H .Wolff, W.H.C Burgdorf: Dermatology Second,Completely Revised Edition, Springer2. Prof. Louis Dubertret: Psoriasis from clinic to therapy Edition Medcom,20053. A lokális antipsoriatikus kezelés uj irányvonalai dr Hoffer Gábor II.BudapestiBfirgyógyászati Továbbképzfi Tanfolyam Faragó, Katalin MD, Dermatologist4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasiscauses as much disability as other major medical diseases. J Am Acad Dermatol1999; 41: 401–407.5. Levi-Schaffer F, Shani J, Politi Y, Rubinchik E, Brenner S. Inhibition ofproliferation of psoriatic and healthy fibroblasts in cell culture by selected Dead-sea salts. Pharmacology 1996; 52: 321–328.
  16. 16. 16Appendix 1I. ATOPIC DERMATITISClinical test for ALOCADO™• A woman of 29 years of age• Suffering from Atopic Dermatitis for 12 years.• Treated with all kinds of medicine, including injections and steroids.• Past two years, no changes.• Start of treatment 8.11.06 – before photo.• Last check 31.12.06 – after photo.• Treated with Alocado™ Cream and Alocado ™ Skin Softener, to be applied three times aday, first Alocado™ Skin Softener and when absorbed, Alocado™ Cream. When itchy,Alocado™ Cream can be applied as much as needed.• In 31.12.06 Alocado™ Gold was added to treat open wounds left on the body,• 10.01.07 wounds are closed; most of the skin is clear, continue maintenance treatmentwith the Alocado™ Cream.
  17. 17. 17II. PSORIASISClinical test for ALOCADO™• 75 years old• PASI index at start 39.2 for the past 15 years no improvement whatever medicine taken.• Very swollen, red and inflamed skin, sometimes very itchy, others not• Some areas are covered with thin plaque.• At current situation, using medicine with steroids, help minor.• Started Alocado™ treatment at the 28/9/06 received Alocado™ Gold for treatinginflammation and Alocado™ Pasta for treating red swollen skin.• The moment stop taking medicines within one week situation worsen to 55 in PASI index(steroid effect).• After 1 month when inflammation reduced, Alocado™ Body oil and Alocado™ Creamfor itching and dry skin were added. So treatment included Alocado™ Gold, Alocado™Body oil, Alocado™ Pasta and Alocado™ Cream, when inflammation was reduced tozero Alocado™ Gold was stopped. After 1 more month at the 3rd of December 2006 thePASI index dropped to 13.2.• No Itching, No scaling, No inflammation, No swelling, No redness (small red dots are theonly thing left, typical to old peoples skin), fingernails grew back better than before (weretreated with Alocado™ Skin Softener).• Over all, pretty satisfying results.• Ongoing treatment – Alocado™ Cream, Alocado™ Body oil and Alocado™ SkinSoftener for maintenance.
  18. 18. 18III. PSORIASISClinical test for ALOCADO™• 68 years old lady• PASI index at start 26, for the past 10 years no improvement whatever medicine taken.• Very swollen, very red and extremely inflamed skin, amazingly no itching.• At current situation, gave up on treatment for several years.• Started Alocado™ treatment at the 28/9/06 received Alocado™ Gold for treatinginflammation and Alocado™ Pasta for treating red swollen skin and Alocado™ Creamfor dry skin.• After 1 month of treatment, PASI index dropped to 13, inflammation reduced and at onearea only pinkish coloration left. (Patient refuse to stop taking the Alocado™ Goldalthough inflammation was reduced, we let it stay).• After two months PASI index 5 and less, No Itching, No scaling, No inflammation, Noswelling, No redness but very light almost unnoticeable pink.• Over all, pretty satisfying results.• Ongoing treatment – Alocado™ Cream, Alocado™ Body oil and Alocado™ Bath oil formaintenance.

×